Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Chimerix, Inc. (CMRX : NSDQ)
 
 • Company Description   
Chimerix, Inc. engages in the discovery, development and commercialization of oral antiviral therapeutics for various medical needs. The Company is developing various product candidates for the treatment of dsDNA viruses, HIV, hepatitis C, influenza and smallpox which are under different phases of clinical development. It is also screening our proprietary Chimerix Chemical Library for compounds with activity against dengue virus, malaria and tuberculosis. Chimerix, Inc. is headquartered in Durham, North Carolina.

Number of Employees: 87

 
 • Price / Volume Information   
Yesterday's Closing Price: $2.35 Daily Weekly Monthly
20 Day Moving Average: 4,174,082 shares
Shares Outstanding: 87.44 (millions)
Market Capitalization: $205.47 (millions)
Beta: 1.28
52 Week High: $9.29
52 Week Low: $1.57
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -51.04% -44.86%
12 Week -57.19% -52.94%
Year To Date -63.45% -58.19%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
2505 MERIDIAN PARKWAY SUITE 100
-
DURHAM,NC 27713
USA
ph: 919-806-1074
fax: 919-806-1146
ir@chimerix.com http://www.chimerix.com
 
 • General Corporate Information   
Officers
Michael T. Andriole - Chief Executive Officer; President and Director
Martha J. Demski - Chairman of the Board of Directors
Michael T. Andriole - Chief Business and Financial Officer
David Jakeman - Executive Director of Finance and Accounting
Catherine L. Gilliss - Directors

Peer Information
Chimerix, Inc. (BJCT)
Chimerix, Inc. (CADMQ)
Chimerix, Inc. (APNO)
Chimerix, Inc. (UPDC)
Chimerix, Inc. (IMTIQ)
Chimerix, Inc. (CYGN)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED PRODUCTS
Sector: Medical
CUSIP: 16934W106
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 87.44
Most Recent Split Date: (:1)
Beta: 1.28
Market Capitalization: $205.47 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.24 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $1.58 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 1.49
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 4.30
Price/Cash Flow: -
Price / Sales: 367.58
EPS Growth
vs. Year Ago Period: -55.56%
vs. Previous Quarter: 37.78%
Sales Growth
vs. Year Ago Period: -98.95%
vs. Previous Quarter: -67.39%
ROE
03/31/22 - -118.41
12/31/21 - -84.90
09/30/21 - -58.06
ROA
03/31/22 - -90.18
12/31/21 - -67.01
09/30/21 - -47.77
Current Ratio
03/31/22 - 4.11
12/31/21 - 3.20
09/30/21 - 4.89
Quick Ratio
03/31/22 - -
12/31/21 - 3.11
09/30/21 - 4.83
Operating Margin
03/31/22 - -17,994.28
12/31/21 - -4,565.23
09/30/21 - -2,047.92
Net Margin
03/31/22 - -17,994.28
12/31/21 - -8,753.71
09/30/21 - -4,762.96
Pre-Tax Margin
03/31/22 - -17,994.27
12/31/21 - -8,753.71
09/30/21 - -4,762.96
Book Value
03/31/22 - 0.55
12/31/21 - 0.79
09/30/21 - 1.21
Inventory Turnover
03/31/22 - 0.06
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Equity
03/31/22 - 0.01
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.52
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©